I need to note that the filing content appears to be cut off - it ends mid-balance sheet. I'll work with what's available, which still contains substantive financial disclosure content well above 150 words.

NovoCure Limited filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC, disclosing consolidated balance sheet data and other financial information as of that date.

Key Highlights

  • Total assets: NovoCure reported total assets of $828,708 thousand as of September 30, 2026, up from $804,326 thousand as of December 31, 2025.
  • Cash and cash equivalents: The company held $96,734 thousand in cash and cash equivalents at September 30, 2026, compared with $93,548 thousand at year-end 2025.
  • Short-term investments: Short-term investments stood at $366,745 thousand, up from $354,126 thousand at December 31, 2025.
  • Trade receivables: Trade receivables, net, increased to $108,260 thousand from $89,435 thousand at December 31, 2025.
  • Shares outstanding: As of October 23, 2026, the company had 116,915,959 ordinary shares outstanding, according to the filing.
  • Field equipment: Net field equipment grew to $28,362 thousand from $22,066 thousand at December 31, 2025.

NovoCure Balance Sheet Expansion in the Quarter Ended September 30, 2026

NovoCure Limited (NASDAQ:NVCR), a Jersey-incorporated company, filed its Form 10-Q for the quarterly period ended September 30, 2026, on October 29, 2026. According to the filing, total current assets reached $673,519 thousand at September 30, 2026, rising from $646,731 thousand at December 31, 2025. The increase was driven in part by higher trade receivables, which grew to $108,260 thousand from $89,435 thousand over the same period, and by higher short-term investments of $366,745 thousand versus $354,126 thousand at year-end 2025.

The filing reported total long-term assets of $155,189 thousand at September 30, 2026, compared with $157,595 thousand at December 31, 2025. Within long-term assets, property and equipment, net, declined slightly to $72,667 thousand from $77,606 thousand, while field equipment, net, increased to $28,362 thousand from $22,066 thousand. Right-of-use assets were $43,063 thousand, down from $47,327 thousand at December 31, 2025.

The company noted that its products include devices marketed under the brand names "Optune Gio," "Optune Lua," and "Optune Pax," as well as related software and tools supporting Tumor Treating Fields ("TTFields") therapy. The filing states that 116,915,959 ordinary shares of no par value were outstanding as of October 23, 2026. NovoCure is classified as a large accelerated filer. The report contains forward-looking statements that, according to the filing, are subject to risks and uncertainties described under Part I, Item 1A of the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed February 26, 2026.

What Was Disclosed

NovoCure's Form 10-Q for Q3 2026 disclosed consolidated balance sheet data showing total assets of $828,708 thousand at September 30, 2026, with 116,915,959 ordinary shares outstanding as of October 23, 2026, and identified the company as a large accelerated filer listed on NASDAQ.